Frontiers in Immunology | Cancer Immunity and Immunotherapy

Review

Published on 21 Mar 2025

The role of B2M in cancer immunotherapy resistance: function, resistance mechanism, and reversal strategies

in Cancer Immunity and Immunotherapy

Xiaowen Han
Jiayi Zhang
Weidong Li
Xiaodong Huang
Xueyan Wang
Bofang Wang
Lei Gao
Hao Chen

Frontiers in Immunology

doi 10.3389/fimmu.2025.1512509

865 views
2 citations

Original Research

Published on 21 Mar 2025

Exploration of SUSD3 in pan-cancer: studying its role, predictive analysis, and biological significance in various malignant tumors in humans

in Cancer Immunity and Immunotherapy

Fei Zhong
Shining Mao
Shuangfu Peng
Jiaqi Li
YanTeng Xie
Ziqian Xia
Chao Chen
Aijun Sun
Shasha Zhang
Shiyan Wang

Frontiers in Immunology

doi 10.3389/fimmu.2025.1521965

709 views

Review

Accepted on 20 Mar 2025

ANO1: Central role and clinical significance in nonneoplastic and neoplastic diseases

in Cancer Immunity and Immunotherapy

Yanghao Hu
Yifei Zhang
Jiali He
Huihuang Rao
Duomi Zhang
Zhisen Shen
Chongchang Zhou

Frontiers in Immunology

doi 10.3389/fimmu.2025.1570333

Correction

Published on 20 Mar 2025

Corrigendum: Increased neutrophil counts are associated with poor overall survival in patients with colorectal cancer: a five-year retrospective analysis

in Cancer Immunity and Immunotherapy

Libia Alejandra Garcia-Flores
María Teresa Dawid De Vera
Jesus Pilo
Alejandro Rego
Gema Gomez-Casado
Isabel Arranz-Salas
Isabel Hierro Martín
Julia Alcaide
Esperanza Torres
Almudena Ortega-Gomez

Frontiers in Immunology

doi 10.3389/fimmu.2025.1583828

363 views

Original Research

Published on 20 Mar 2025

Global research trends of tumor microenvironment in non-small cell lung cancer with epidermal growth factor receptor mutation: a bibliometric analysis from 2014 to 2023

in Cancer Immunity and Immunotherapy

Xiaoyan Chang
Chenghao Wang
Fei Wang
Linyou Zhang

Frontiers in Immunology

doi 10.3389/fimmu.2025.1555216

928 views

Review

Published on 20 Mar 2025

ETS-1 in tumor immunology: implications for novel anti-cancer strategies

in Cancer Immunity and Immunotherapy

SiYu Wang
Lei Wan
XiaoJun Zhang
HaoXiang Fang
MengYu Zhang
Feng Li
DaWei Yan

Frontiers in Immunology

doi 10.3389/fimmu.2025.1526368

847 views

Correction

Published on 20 Mar 2025

Corrigendum: Targeting mitochondrial damage: shining a new light on immunotherapy

in Cancer Immunity and Immunotherapy

Wenjuan Zeng
Menghui Wang
Yuxin Zhang
Taicheng Zhou
Zhen Zong

Frontiers in Immunology

doi 10.3389/fimmu.2025.1591209

273 views

Original Research

Published on 20 Mar 2025

Association between oxidative balance score and all-cause and cancer-specific mortality among cancer survivors

in Cancer Immunity and Immunotherapy

Qingmei Gao
Xinfang Zhu
Mengke Chen
Rong Xia
Qi Zhang

Frontiers in Immunology

doi 10.3389/fimmu.2025.1541675

841 views

Original Research

Published on 20 Mar 2025

Hexokinase2-engineered T cells display increased anti-tumor function

in Cancer Immunity and Immunotherapy

Raphaëlle Toledano Zur
Shiran Didi Zurinam
Maria Radman
Elia Funaro Balouka
Tatiana Borodianskiy-Shteinberg
Dieter Saur
Cyrille J. Cohen

Frontiers in Immunology

doi 10.3389/fimmu.2025.1477929

610 views

Original Research

Accepted on 19 Mar 2025

Olverembatinib (HQP1351)-based therapy in adults with relapsed or refractory Philadelphia chromosome-positive acute lymphoblastic leukemia or blast phase chronic myeloid leukemia: results of a real-world study

in Cancer Immunity and Immunotherapy

Ziyu Wen
Zhi Liu
XU YE
Zhiping Fan
Ren Lin
Fen Huang
Li Xuan
Xiaofang Li
Hua Jin
Min Dai

Frontiers in Immunology

doi 10.3389/fimmu.2025.1546371

120 views

Original Research

Accepted on 19 Mar 2025

Patient-derived pancreatic tumor bacteria exhibit oncogenic properties and are recognized by MAIT cells in tumor spheroids

in Cancer Immunity and Immunotherapy

Poojabahen Tajpara
Michał Jacek Sobkowiak
Katie Healy
Sabrina NAUD
Beate Gündel
Asif Halimi
Zara Ahmad Khan
Giorgio Gabarrini
Sylvie Le Guyader
Gabriela Imreh

Frontiers in Immunology

doi 10.3389/fimmu.2025.1553034

130 views

Case Report

Published on 19 Mar 2025

Case Report: Successful immune checkpoint inhibitor rechallenge after sintilimab-induced Guillain-Barré syndrome

in Cancer Immunity and Immunotherapy

Lin Ye
Wan Rong Yue
Hao Shi
Jian Ren Li
Yu Ya Qun

Frontiers in Immunology

doi 10.3389/fimmu.2025.1546886

849 views

Original Research

Published on 19 Mar 2025

A syringeable immunotherapeutic hydrogel enhances T cell immunity via in-situ activation of STING pathway for advanced breast cancer postoperative therapy

in Cancer Immunity and Immunotherapy

Baozhen Zhang
Min Li
Jiahua Ji
Xinghui Si
Xiaojiao Yin
Guofeng Ji
Liqun Ren
Haochen Yao

Frontiers in Immunology

doi 10.3389/fimmu.2025.1523436

597 views

Original Research

Published on 19 Mar 2025

Celecoxib prevents malignant progression of smoking-induced lung tumors via suppression of the COX-2/PGE2 signaling pathway in mice

in Cancer Immunity and Immunotherapy

Kaori Sakurai
Shotaro Chubachi
Jun Miyata
Junko Hamamoto
Tatsuro Naganuma
Takashi Shimada
Shiro Otake
Shingo Nakayama
Hidehiro Irie
Akihiro Tsutsumi

Frontiers in Immunology

doi 10.3389/fimmu.2025.1557790

1,067 views

Original Research

Published on 19 Mar 2025

Oropharyngeal carcinomas induce circulating monocytes to express a TAM-like pro-tumor expression profile that suppresses T-cell proliferation

in Cancer Immunity and Immunotherapy

Christopher J. Papayannakos
Mohd Israr
James A. DeVoti
Fung Lam
Arnon Arazi
Douglas K. Frank
Dev P. Kamdar
Lucio M. Pereira
Nagashree Seetharamu
Bettie M. Steinberg

Frontiers in Immunology

doi 10.3389/fimmu.2025.1539780

713 views

Original Research

Published on 18 Mar 2025

Enhancing pancreatic cancer treatment: the role of H101 oncolytic virus in irreversible electroporation

in Cancer Immunity and Immunotherapy

Pu Xi
Dejun Zeng
Miao Chen
Lingmin Jiang
Yu Zhang
Dailei Qin
Zehui Yao
Chaobin He

Frontiers in Immunology

doi 10.3389/fimmu.2025.1546242

919 views
1 citation